A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels

2001 ◽  
Vol 120 (5) ◽  
pp. A279-A280 ◽  
Author(s):  
Bruce R. Yacyshyn ◽  
W.Y. Chey ◽  
J Goff ◽  
B Salzberg ◽  
R Baerg ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Improvement ◽  
Controlled Trial ◽  
Serum Levels ◽  
High Serum ◽  
Steroid Dependent

scholarly journals Serum Cytokine Profiles in Children with Crohn’s Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Ekaterina Vasilyeva ◽  
Sayar Abdulkhakov ◽  
Georgi Cherepnev ◽  
Ekaterina Martynova ◽  
Irina Mayanskaya ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Onset ◽  
Serum Levels ◽  
High Serum ◽  
Acute Stage ◽  
Chronic Inflammatory Bowel Disease ◽  
Serum Cytokine ◽  
Cytokine Profiles ◽  
Age Dependent

Crohn’s disease (CD) is a chronic inflammatory bowel disease that can be diagnosed at any age. There are two major patient groups based on diagnosis of this disease, before or after the age of 20 (juvenile/adolescent or adult), with disease progression in adults usually milder than in juvenile CD patients. Immune mechanisms have been suggested to play an important role in CD pathogenesis, with cytokines governing the development of the immune response. Upregulation of inflammatory cytokines in serum of juvenile and adult CD patients has been documented; still little is known about age-dependent differences in serum cytokine profiles of CD patients. We applied multiplex technology to analyze serum levels of 12 cytokines in juveniles and adults. We show that during the acute stage of the disease all CD patients have high serum levels of CXCL10, which remains upregulated during remission. Increased serum levels of TNF-αand IL-6 during the acute stage was characteristic of juvenile CD patients, whereas adult CD patients had upregulated levels of GM-CSF and IFN-γ. Taken together, these results demonstrate age-dependent differences in cytokine profiles, which may affect the pathogenesis of CD in patients at different ages of disease onset.

Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease?

2003 ◽  
Vol 15 (12) ◽  
pp. 1281-1285 ◽  
Author(s):  
Marieluise Harrer ◽  
Walter Reinisch ◽  
Clemens Dejaco ◽  
Verena Kratzer ◽  
Maria Gmeiner ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Serum Levels ◽  
High Serum ◽  
Gut Barrier

Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients: A Randomized Placebo-Controlled Trial

2006 ◽  
Vol 130 (4) ◽  
pp. 1054-1061 ◽  
Author(s):  
Marc LÉmann ◽  
Jean–Yves Mary ◽  
Bernard Duclos ◽  
Michel Veyrac ◽  
Jean–Louis Dupas ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Steroid Dependent

Safety of switching systemic steroids to budesonide modified-release capsules in steroid-dependent patients with inactive Crohn's disease

2001 ◽  
Vol 120 (5) ◽  
pp. A749-A749
Author(s):  
A CORTOT ◽  
J COLOMBEL ◽  
P RUTGEERTS ◽  
K LAURITSEN ◽  
H MALCHOW ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Modified Release ◽  
Systemic Steroids ◽  
Steroid Dependent
Sign in / Sign up

Export Citation Format

Share Document